Showing results (11-20 of 38) with videos related to
Sort By:
Pageof 4
JAMA Oncology|July 31, 2020
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical TrialOliver Klein, Damien Kee, Adnan Nagrial, et al.Molecular Imaging and Biology|June 19, 2025
Poor Diagnostic Performance of the Melanin-Binding Tracer [18 F]MEL050 in Human Melanoma Indicates Biological HeterogeneityRobert E Ware, Damien Kee, Peter Roselt, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare CancersOliver Klein, Damien Kee, Ben Markman, et al.Journal for Immunotherapy of Cancer|November 16, 2021
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trialOliver Klein, Damien Kee, Bo Gao, et al.JCO Clinical Cancer Informatics|February 22, 2020
CART-WHEEL.org: An Ethically Approved Online Database for Patient-Entered Data to Facilitate Rare Cancer ResearchDamien Kee, Clare Parker, Susie Bae, et al.Virchows Archiv : an International Journal of Pathology|August 12, 2019
Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinomaStefan Porubsky, Peter Jessup, Damien Kee, et al.European Journal of Nuclear Medicine and Molecular Imaging|April 28, 2020
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatmentAmir Iravani, Medhat M Osman, Alison M Weppler, et al.The Lancet. Oncology|July 20, 2014
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b studyAntoni Ribas, Rene Gonzalez, Anna Pavlick, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2011
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitorsPatrick A Oberholzer, Damien Kee, Piotr Dziunycz, et al.Nature Medicine|March 1, 2024
A gut microbial signature for combination immune checkpoint blockade across cancer typesAshray Gunjur, Yan Shao, Timothy Rozday, et al.Pageof 4